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Introduction
Chronic inﬂ  ammation is a risk factor for bone loss. Many 
chronic inﬂ   ammatory disorders, such as rheumatoid 
arthritis (RA), ankylosing spondylitis, inﬂ  ammatory 
bowel disease and even low-grade inﬂ  ammation in other-
wise healthy individuals, have been linked to an increased 
fracture risk [1-5]. RA is of particular interest as both 
locally aﬀ  ected bones and sites distant of joint inﬂ  am-
mation are prone to bone loss.
Chronic inﬂ  ammation is the key mediator for local and 
systemic bone loss in RA patients. In RA patients, 
cytokines are abundantly present in the arthritic syno-
vium as well as secreted into the systemic circulation 
[6,7]. Th  e discovery of RANKL (Receptor activator of 
NF-kB ligand) in 1998 as a crucial regulator of osteo-
clastogenesis opened avenues for the research of 
arthritis-driven bone loss [8]. Since then, several pro-
inﬂ  ammatory cytokines have been identiﬁ  ed as direct or 
indirect stimulators of osteoclast diﬀ  erentiation, survival 
and activity. Th   is review comprises the knowledge on the 
most important cytokines, which are both involved in RA 
pathophysiology and documented drivers of osteoclast 
diﬀ  erentiation, survival or activation (Figure 1). In addi-
tion to their pro-resorbing role, other cytokines can also 
act anti-osteoclastogenically, which is reviewed in the 
accom  panying article of Zhao and Ivashkiv. Th  is is 
especially evident, as other arthritic disorders such as 
psoriatic arthritis are characterised by strong repair 
responses within aﬀ   ected joints [9]. Th  e balance of 
osteoclastogenic and anti-osteoclastogenic mediators 
thus decides the fate of bone destruction.
RANKL
RANKL is a member of the TNF family of cytokines and 
plays a key role in bone resorption. Osteoclasts are the 
sole bone resorbing cell. Th  ey are formed by fusion of 
mononuclear cells of the monocyte/macrophage lineage, 
but dendritic cells could also serve as osteoclast pre-
cursors [10-12]. RANKL is a necessary factor for the 
diﬀ  er  entiation of osteoclasts. Mice deﬁ  cient for RANKL 
develop severe osteopetrosis due to a complete lack of 
osteoclastogenesis [13]. RANKL also serves as survival 
factor and activates osteoclasts. Th   e physiological inhibi-
tor of RANKL is osteoprotegerin (OPG), a decoy receptor 
that binds RANKL. OPG-deﬁ  cient mice exhibit severe 
osteoporosis [14]. Th  e main sources of RANKL are 
osteoblasts but RANKL can also be expressed in synovial 
cells, activated T cells, mature B cells and natural killer 
cells [15-18]. Expression of RANKL is upregulated by 
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© 2011 BioMed Central Ltdpara  thyroid hormone, 1,25(OH)2D3 and several pro-
inﬂ  am  ma  tory cytokines, including IL-1, IL-6, IL-17 and 
TNF-α [8,19-21]. RANKL functions both as a membrane-
anchored molecule and as a soluble molecule. Both forms 
bind to RANK, the receptor of RANKL. RANK is 
expressed on osteoclast precursors and mature osteo-
clasts [22]. In vivo, RANKL-deﬁ  cient mice are protected 
from bone erosions in the serum transfer model of 
arthritis [23]. OPG treatment protects human TNF-α 
transgenic mice from bone destruction [24]. In a rat 
collagen-induced arthritis (CIA) model, OPG inhibited 
bone destruction as well [25]. In these models, inhibition 
of RANKL aﬀ  ects only bone destruction and not inﬂ  am-
mation. Denosumab, a humanized antibody against 
RANKL, is currently being evaluated in clinical trials. 
Appli  cation of denosumab inhibits glucocorticoid-
induced bone loss in mice [26]. In a phase II study, the 
addition of denosumab to methotrexate treatment 
inhibited structural bone damage in patients with RA 
[27].
Tumour necrosis factor α
Activated macrophages but also synovial ﬁ  broblasts, 
T   cells, B cells, natural killer cells, osteoblasts and 
Figure 1. Cytokines activating osteoclastogenesis in rheumatoid arthritis. TNF, IL-1, IL-6 and IL-17 upregulate expression of RANKL (receptor 
activator of NF-kB ligand) in osteoblasts and synovial fi  broblasts. RANKL mediates diff  erentiation, survival and activation of osteoclasts. TNF, 
produced by fi  broblasts and macrophages, promotes diff  erentiation and survival of osteoclasts. IL-1 supports diff  erentiation, survival and activation 
of osteoclasts. IL-6 and IL-17 promote osteoclastogenesis indirectly. IL-6 is largely produced by fi  broblasts and macrophages; it enhances the 
expression of RANKL and contributes to the induction of Th17 cells. Th17 cells secrete IL-17, but a main source of synovial IL-17 is probably mast 
cells. IL-17 induces the expression of RANKL in osteoblasts and fi  broblasts and enhances secretion of pro-infl  ammatory cytokines by macrophages. 
Macrophage colony-stimulating factor (M-CSF) and IL-34 promote diff  erentiation and activation of osteoclasts; IL-33 supports osteoclast 
diff  erentiation. TGF, transforming growth factor.
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TNF [28,29]. Both soluble and membrane-bound TNF 
bind to the TNF receptors TNFR1 (p55) and TNFR2 
(p75). TNFR1 mediates most of the biological eﬀ  ects of 
TNF. Osteoclasts and its precursors express both TNFR1 
and TNFR2 [30-32]. TNF upregulates RANK expression 
and can thus enhance osteoclastogenesis [33]. TNF may 
also directly act on osteoclast precursors, but whether 
this is truly independent of RANKL signalling is still the 
subject of debate (reviewed in [34]). TNF promotes the 
survival of mature osteoclasts, but does not eﬃ   ciently 
activate osteoclasts [34,35]. Kitaura and colleagues 
demonstrated TNF-dependent secretion of macrophage 
colony-stimulating factor (M-CSF) by bone marrow 
stromal cells that induces osteoclastogenesis more 
eﬃ   ciently than the direct stimulation of osteoclast pre-
cursors by TNF. Th  e relevance of this ﬁ  nding is under-
lined by inhibition of osteoclastogenesis despite persis-
tence of inﬂ  ammation in a serum-transfer arthritis model 
using an anti-M-CSF receptor (c-fms) antibody [36].
TNF further supports osteoclastogenesis by interacting 
with the wingless (Wnt) signalling pathway. TNF is a 
strong inducer of Dkk-1 expression, a Wnt antagonist. 
Dkk-1 inhibits Wnt signalling by binding to LRP-5 (low 
density lipoprotein-coupled receptor related protein-5) 
and LRP-6 and the coreceptor Kremen-1/2 [37]. Active 
Wnt signalling induces OPG expression and therefore 
decreases the RANKL/OPG ratio, thus acting anti-
osteoclastogenically [38]. Consequently, Dkk-1 promotes 
osteoclastogenesis by increasing the RANKL/OPG ratio. 
In RA patients, elevated serum levels of Dkk-1 have been 
observed. After initiation of anti-TNF therapy, serum 
levels of Dkk-1 decrease. Expression of Dkk-1 is also 
enhanced in animal models of erosive arthritis, such as 
human TNF transgenic mice, CIA and glucose-6-
phosphate isomerase-induced arthritis [39].
Th   e relevance of TNF for arthritic bone destruction has 
been demonstrated in several experimental models and 
was ﬁ  nally conﬁ  rmed by clinical trials. In vivo, human 
TNF transgenic mice develop severe arthritis with 
chronic synovial inﬂ  ammation, cartilage destruction, and 
systemic and local bone loss [40]. Th   e latter pathology is 
quite unique, as many other rodent arthritis models are 
characterized by strong repair responses, which is rarely 
seen in RA. In CIA, the application of TNF-speciﬁ  c 
neutralizing antibodies reduced disease activity and bone 
damage [41]. Th   e results in TNF-deﬁ  cient mice are not as 
clear. Using the serum transfer model of arthritis, most 
TNF-deﬁ   cient mice develop no clinical or histological 
signs of arthritis, but one-third of mice showed clinical 
signs of arthritis [42]. Th  e  eﬃ   cacy and safety of the TNF 
antagonists inﬂ  iximab, etanercept, adalimumab, golimu-
mab and certolizumab in RA patients were demonstrated 
in several clinical studies and these drugs are now 
frequently used in clinical practice [43]. Interestingly, RA 
patients clinically not responding to anti-TNF treatment 
are still protected from development of new bone 
erosions. Th   is underlines the important role of TNF for 
arthritic bone destruction.
Interleukin-1
In RA joints, activated macrophages and synovial 
ﬁ  broblasts are sources of IL-1 production [44,45]. IL-1α 
and IL-1β share only 24% amino acid sequence identity 
but have largely identical biological functions mediated 
through the receptor IL-1R1 [46,47]. IL-1 receptor 
antagonist (IL1-Ra) is a soluble protein that competes 
with IL-1 for binding to IL-1R1 [48]. Th  us, the IL-1/
IL-1Ra ratio has to increase to induce IL-1R1 activation. 
IL-1R1 and the decoy receptor IL-1R2 are expressed in 
osteoclasts. Th   ere is higher expression of IL-1R1 in large 
osteoclasts than in small osteoclasts [49]. Th  e  mechanism 
has not yet been completely established, but several in 
vitro studies provide evidence that IL-1 plays a signiﬁ  cant 
role in osteoclast physiology. IL-1 promotes the fusion of 
osteoclast precursors [50] and prolongs the survival of 
mature osteoclasts [51]. It is also important for osteoclast 
activation in vitro [31,52].
In vivo, IL-1 is a key regulatory cytokine in mouse 
models of inﬂ  ammatory arthritis. Overexpression of IL1-
α or IL-1β as well as deletion of IL-1Ra leads to 
development of arthritis with destruction of cartilage and 
bone [45,53-55]. Mice deﬁ   cient of IL-1R1 develop no 
arthritis in a model of serum transfer arthritis [42]. In 
human TNF transgenic mice deﬁ  cient for IL-1 signalling, 
cartilage destruction was completely blocked and bone 
destruction partly reduced despite the presence of 
synovial inﬂ   ammation [56]. Recent data show no 
systemic inﬂ  ammatory bone loss in these IL-1-deﬁ  cient 
human TNF transgenic mice in spite of ongoing inﬂ  am-
matory arthritis [57]. Th  ese data indicate that TNF-
induced local bone destruction and systemic inﬂ  amma-
tory bone loss are largely dependent on IL-1. Th  us,  IL-1 
is an important downstream mediator of TNF. Th  ese  in 
vivo data are supported by in vitro evidence showing that 
TNF-induced synthesis of RANKL is inhibited by IL-1Ra 
[58]. In contrast to these in vivo and in vitro data, 
targeting IL-1 has not yet provided powerful therapeutics 
for the treatment of RA [59]. However, few data exist 
regarding the bone-protective properties of IL-1 neutrali-
zation in RA patients.
Interleukin-6
IL-6 expression in RA synovial tissue has been localized 
to synovial ﬁ  broblasts, macrophages and T cells [60,61]. 
Th  ere are two forms of the IL-6 receptor, a trans  mem-
brane variant and a soluble variant. Th  e  transmem  brane 
form consists of an 80-kDa chain speciﬁ  c for IL-6 and the 
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Th  is transmembrane form of the IL-6 receptor is only 
expressed in hepatocytes, monocytes/macrophages, 
osteoblasts and other leukocytes, while gp130 is ex-
pressed on almost all cells [62,63]. Th   e soluble receptor 
binds IL-6 and activates gp130 on cells that do not 
express the transmembrane receptor [62]. Th  is soluble 
receptor is found in many body ﬂ  uids, including serum 
and synovial ﬂ  uid [64]. IL-6 is elevated in serum and 
synovial ﬂ  uid of RA patients [65]. IL-6-deﬁ  cient mice are 
protected from ovariectomy-induced bone loss and show 
delayed bone fracture healing related to a decreased 
number of osteoclasts [66,67]. IL-6 overexpression is 
associated with enhanced bone resorption and increased 
osteoclast numbers and activity [68]. Th   ese data suggest 
an activating eﬀ  ect of IL-6 signalling on bone resorption.
In vitro, IL-6 stimulates the release of RANKL by osteo-
blasts and together with transforming growth factor-β 
and IL-1 promotes the development of Th   17 cells [69-71]. 
A recent study showed reduced in vitro osteoclast 
diﬀ  erentiation due to the blockade of the IL-6 receptor 
[72]. Th   ere is also recent in vitro evidence of an inhibitory 
eﬀ   ect of IL-6 on osteoclastogenesis [73,74]. However, 
these models do not consider potential eﬀ  ects of other 
cells and cytokines and the in vivo relevance of these in 
vitro ﬁ  ndings is unclear [75].
IL-6-deﬁ   cient mice are protected from CIA and 
adjuvant-induced arthritis [76-78]. In contrast, the IL-6-
deﬁ   cient mice develop arthritis in the K/BxN serum 
transfer model [42]. While overexpression of human IL-6 
does not induce polyarthritis, an activating mutation in 
the mouse gp130 gene causes autoimmune polyarthritis 
[79,80]. Th  e application of an IL-6 receptor (IL-6R) 
neutralizing antibody in CIA reduced disease activity 
[81]. In human TNF transgenic mice, an anti-IL-6R anti-
body did not inhibit joint inﬂ   ammation but reduced 
osteo  clast formation in the inﬂ   amed joints and bone 
erosion [72]. In contrast to the diﬀ  erent experimental ﬁ  nd-
ings, the IL-6R-speciﬁ  c antibody tocilizumab eﬃ   ci  ently 
reduces disease activity and radiographic progres  sion in 
RA patients and is now used in clinical practice [59].
Interleukin-17
IL-17 is present in synovial ﬂ  uid of RA patients and its 
expression has been detected within the inﬂ  amed 
synovium in Th  17 and other cells [20,82,83]. Recent 
evidence suggests that cells other than Th   17 cells, such as 
mast cells, are probably a major source of IL-17 produc-
tion within human arthritic joints [84]. Th  ere is good 
evidence for an important role of IL-17 in osteoclasto-
genesis, but the detailed mechanism is not yet completely 
understood [22].
In mice, the severity of CIA is reduced in IL-17-
deﬁ  cient animals and the local overexpression of IL-17 in 
a joint enhances severity of arthritis [85,86]. Th  e treat-
ment of arthritic mice with an anti-IL-17 antibody 
reduces joint inﬂ   ammation, cartilage destruction and 
bone erosion in CIA and antigen-induced arthritis 
[87,88].  In vitro, IL-17 stimulates osteoclastogenesis 
prefer  entially indirectly [20]. In vitro studies show that, 
on the one hand, IL-17 elevates RANKL expression in 
osteoblasts and ﬁ  broblasts, and on the other, it induces 
the secretion of pro-inﬂ  ammatory cytokines such as IL-6 
and IL-8 by ﬁ  broblasts and endothelial and epithelial cells 
and the secretion of TNF and IL-1 from monocytes 
[22,89-91]. Recent data provide evidence for an additional 
direct eﬀ   ect of IL-17 on osteoclast diﬀ  erentiation.  In 
vitro, IL-17 upregulates RANK on human osteoclast 
precursors to sensitize them to RANKL [92]. Another 
recent study demonstrated that IL-17 induces osteo-
clasto  genesis in cultures of human CD11b-positive cells 
in the absence of osteoblasts or exogenous RANKL. Th  is 
is blocked by the application of OPG or inﬂ  iximab, 
suggest  ing a RANKL- and TNF-dependent mechanism 
[93]. Further investigation is necessary to identify the 
exact mechanism of IL-17-induced osteoclastogenesis. 
Ongoing clinical trials are analysing the eﬃ   cacy of anti-
IL-17 antibodies in RA patients.
Macrophage colony-stimulating factor
M-CSF is a key cytokine providing osteoclast diﬀ  eren-
tiation signals [94,95]. It is secreted by synovial 
ﬁ  broblasts, osteoblasts, macrophages and T cells in RA 
patients [96-98]. Th  e importance of M-CSF-induced 
osteo  clastogenesis is conﬁ  rmed in mouse models: op/op 
mice, which fail to express functional M-CSF, and c-fms 
(the M-CSF receptor) deﬁ  cient mice show an osteoclast-
poor osteopetrotic phenotype [99,100]. In vitro, M-CSF 
modulates multiple steps in human osteoclastogenesis, 
including proliferation, diﬀ  erentiation and fusion of pre-
cursors and at later diﬀ  erentiation stages bone resorbing 
activity but not survival [101]. Th   e binding of M-CSF to 
c-fms leads to the activation of the ERK-Akt signalling 
pathway [102-104].
Intracellular signalling
Th  e stimulation of osteoclasts with RANKL leads to 
potent activation of NFATc1 (Nuclear factor of activated 
T cells, cytoplasmic 1), as demonstrated by gene expres-
sion proﬁ  ling (Figure 2) [105]. NFATc1 is a key regulator 
of osteo  clast diﬀ  erentiation in vitro and in vivo; it induces 
osteoclast-speciﬁ  c genes, including TNF-receptor asso-
ciated protein (TRAP), calcitonin receptor and cathepsin 
K, and it positively regulates its own promoter. Th  e 
activation of NFATc1 is regulated by RANKL in two 
ways: the NF-κB/AP-1/c-fos pathway and calcium signal-
ling [105]. RANKL binds to its receptor RANK, which 
leads to the binding of RANK to its main adaptor 
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TRAF5 is also involved in RANKL-mediated osteo-
clastogenesis [106]. Th   is complex activates JNK, p38 and 
NF-κB [107]. In vitro, osteoclastogenesis is impaired in 
monocytes lacking p38α [108].
NF-κB is a family of dimeric transcription factors. In 
mammals there are ﬁ  ve proteins: Rel (cRel), RelA (p65), 
RelB, NFκB1 (p50) and NFκB2 (p52) [109]. p50/p52-/- 
mice develop osteopetrosis while p50-/- mice show no 
bone phenotype [109-111]. Th  ere is a classical and an 
alternative NF-κB signalling pathway. Th   e classical path-
way includes activation of IκB kinase (IKK)β. Roucco and 
colleagues [112] showed impaired osteoclastogenesis in 
the absence of IKKβ in vitro and in vivo. Th  e  alternative 
pathway includes IKKα and NF-κB-inducing kinase 
(NIK). Osteoclastogenesis depends on IKKα and NIK 
only in vitro but not in vivo [112,113]. Th   us, the classical 
pathway seems to be of greater importance for osteo-
clastogenesis. In addition, IKKβ prevents TNF-induced 
apoptosis of osteoclast precursors [112]. NF-κB induces 
c-fos, cyclic AMP-responsive element-binding protein 
(CREB) and calcium/calmodulin-dependent protein 
kinase type IV (CaMKIV) [114,115].
Th  e AP-1 transcription-factor is a dimeric complex 
composed of c-fos and Jun proteins. c-Fos-deﬁ  cient mice 
develop severe osteopetrosis due to a complete block of 
osteoclastogenesis [116,117]. Mice with conditional 
knock  out of Jun proteins (c-Jun, JunB) show impaired 
osteo  clastogenesis [118,119], and mice expressing domi-
nant negative c-Jun under the control of the TRAP 
promoter develop osteopetrosis [120]. AP-1 DNA bind-
ing activity is upregulated in the synovial tissue of RA 
patients and correlates with disease activity [121]. AP-1 
cooperates with NFATc1, inducing osteoclast-speciﬁ  c 
genes [105].
On the other hand NFATc1 is dependent on calcium 
signalling. Th   e phosphatase calcineurin speciﬁ  cally acti-
vates NFATc1 by dephosphorylating its amino-terminal 
regulatory domain. While the phosphorylated NFATc1 is 
localised in the cytoplasm, the dephosphorylated 
NFATc1 can enter the nucleus. Th  e importance of this 
path  way is shown by the immunosuppressive drug cyclo-
sporine, which inhibits calcineurin [122]. Th  e  activation 
of calcineurin is dependent on calcium and phospho-
lipase C (PLC)γ, which mediates calcium release in the 
cytoplasm [105]. PLCγ2 is the isoform that regulates 
Figure 2. Intracellular signalling during infl  ammation-induced osteoclastogenesis. RANKL (receptor activator of NF-kB ligand) binds to its 
receptor RANK and induces the key regulator of osteoclast diff  erentiation NFATc1 (Nuclear factor of activated T cells, cytoplasmic 1) through two 
diff  erent signalling pathways. On the one hand, RANK recruits TRAF6 (TNF receptor-associated factor 6) and activates NF-κB, JNK, p38, c-fos and 
AP-1. On the other hand, NFATc1 is activated by calcineurin that is in turn activated by elevated calcium in the cytoplasm. Phospholipase C (PLC)γ 
mediates the release of calcium in the cytoplasm; PLCγ is activated by RANK through Btk/Tec and by OSCAR (osteoclast-associated receptor) and 
TREM-2 (triggering receptor expressed by myeloid cells 2) through the Fc receptor gamma chain (FcRγ), DAP12 (DNAX-activating protein of 12 kDa) 
and Syk signalling. TNF binds to its receptor TNFR1, which recruits TRADD (TNFR-associated DD protein) and RIP-1 (Receptor interacting protein-1). 
TNF receptor-associated factor (TRAF)2, TRAF5 and TRAF6 mediate further signalling through NF-κB, JNK and p38. The IL-1 receptor IL-1R1 binds 
MYD88 (myeloid diff  erentiation primary response gene 88) and RAK4, which activates TRAF6 through phosphorylation of IL-1 receptor-activating 
protein kinase (IRAK)2 and IRAK1. After binding IL-6, the IL-6 receptor recruits two gp130 molecules and activates the signal transducer and 
activator of transcription (STAT) pathway and the mitogen-activated protein kinase (MAPK) pathway (JNK, p38, ERK) through gp130. MMP, matrix 
metalloproteinase.
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osteopetrosis independent of PLCγ1 [123]. Th   ere are two 
links between calcium signalling and RANKL. Th  e co-
stimulatory receptors of RANK, OSCAR (osteoclast-
associated receptor) and TREM-2 (triggering receptor 
expressed by myeloid cells 2), activate PLCγ through its 
adaptor proteins DAP12 (DNAX-activating protein of 
12 kDa) and Fc receptor gamma chain (FcRγ) and the 
tyrosin kinase Syk [124,125]. Th   e second link is the Tec 
family tyrosine kinases Tec and Btk, which are activated 
by RANKL and are involved in the phosphorylation of 
PLCγ [126].
TNF signalling in osteoclasts and their precursors is 
primarily mediated by TNFR1. TNFR1 contains a cyto-
plasmic death domain and when unstimulated, this 
domain binds to the death domain of the protein SODD 
(silencer of death domain). TNF binding to TNFR1 leads 
to the release of SODD. Th  is allows the binding of 
TRADD (TNFR-associated DD protein), which recruits 
RIP-1 (receptor interacting protein-1) and TRAF2. Th  is 
TRADD-RIP-1-TRAF2 complex is released from TNFR1 
and activates NFκB, JNK and p38 signalling [30]. TRAF2 
is essential for osteoclastogenesis in vitro [127]. TRAF6 
and TRAF5 also contribute to TNF-dependent osteo-
clasto genesis  in vitro and activate NFκB, JNK and p38 
signalling [106,128,129]. In line with this, TRAF6-
deﬁ  cient mice show severe osteopetrosis [130].
Th  e binding of IL-1 to its receptor IL-1R1 induces a 
conformational change of the receptor. After recruitment 
of IL-1RacP, it binds to MYD88 (myeloid diﬀ  erentiation 
primary response gene 88) and IL-1 receptor-activating 
protein kinase (IRAK)4. Th  is complex recruits TRAF6 
through phosphorylation IRAK2 and IRAK1 [131].
Th  e transmembrane or the soluble IL-6 receptor 
forms a complex with two gp130 molecules after 
binding IL-6. Th  is leads to phosphorylation of Janus 
protein-tyrosine kinase, which causes the activation of 
intracellular signal transduction. gp130 can act though 
two intracellular signalling pathways: the signal trans-
ducer and activator of transcription (STAT) pathway 
and the mitogen-activated protein kinase (MAPK) 
pathway [75]. Th   e mechanism of IL-6 signalling in bone 
turnover is not yet understood. Mice lacking the gp130 
binding site for STAT show no alteration in osteoclast 
activity and one publication indicated that STAT3 
downregulates NFATc1 [132,133]. Mice lacking the 
gp130 binding site for MAPK signalling exhibit 
osteopenia. gp130-deﬁ  cient mice develop osteopenia as 
well, although this mutation results in neonatal lethality 
[133]. A recent study shows that IL-6 suppresses NF-κB 
signalling [73]. Despite these ﬁ   ndings, IL-6 seems to 
have potent osteoclast-activating functions in RA 
patients, as demonstrated by clinical trials using an 
anti  body against the soluble IL-6 receptor.
Other cytokines
Th  e recently discovered cytokine IL-34 binds to the M-
CSF receptor c-fms. In functional studies it promotes 
monocyte viability and the formation of macrophage 
progenitor cells independent of M-CSF. Similar to M-
CSF, IL-34 activates ERK signalling [134]. Baud’Huin and 
colleagues [135] demonstrated that IL-34 was able to 
support RANKL-induced osteoclastogenesis in the 
absence of M-CSF. However, higher concentrations of IL-
34 than of M-CSF are required to exert an equivalent 
activity, probably due to a relatively lower binding aﬃ   nity 
of IL-34 to c-fms. IL-34 activates the ERK-Akt signalling 
pathway in osteoclast progenitors and promotes osteo-
clastogenesis but has no eﬀ  ect on osteoclast survival.
Th  ere is recent evidence that the pro-inﬂ  ammatory 
cytokine IL-33 participates in the pathogenesis of RA. It 
is expressed in the synovium of patients with RA and its 
expression appeared to correlate with the severity of 
inﬂ  ammation [136]. IL-33 acts through the receptor ST2 
[137], which is a member of the Toll-like/IL-1 receptor 
family and activates TRAF6 [138]. Th  e ST2 trans-
membrane form is expressed predominantly on mast 
cells and Th   2 cells. In murine antigen-induced arthritis, 
IL-33 exacerbates disease by activating mast cells [139]. 
Inhibition of IL-33 signalling reduced severity of bone 
erosion in an animal arthritis model [140]. Recent data 
show that IL-33 induces the formation of osteoclasts 
from human monocytes independent of RANKL [141]. 
IL-33 seems to activate MAPKs, NF-κB and the Syk/
PLCγ signalling pathway in human monocytes. In con-
trast, IL-33 was found to inhibit murine osteoclasto-
genesis in vitro and in vivo [142].
Th  ere were previous reports that the culture medium 
of activated T cells directly stimulates osteoclastogenesis 
independent of RANKL [143,144]. Rifas and colleagues 
[145] recently identiﬁ  ed a new cytokine in the medium of 
activated T cells by chromatographic analysis. Th  ey 
called this new cytokine Secreted osteoclastogenic factor 
of activated T-cells (SOFAT). SOFAT induces the forma-
tion of human and mouse functional osteoclasts indepen-
dent of RANKL and is secreted by T cells in a calcineurin-
independent manner. It is derived from a mRNA splice 
variant encoded by the threonin synthase-like 2 gene 
homolog. RANKL-deﬁ  cient mice have no osteoclasts and 
develop no bone erosions despite severe inﬂ  ammation in 
the case of arthritis [13,23]. Th  ese  in vivo data show no 
relevant osteoclastogenesis independent of RANKL. 
Further investigation is needed to characterize the role of 
SOFAT in osteoclastogenesis.
In vitro data demonstrated that IL-15 directly promotes 
diﬀ  erentiation of rodent osteoclast progenitors into pre-
osteoclasts [146] and neutralization of IL-15 prevented 
bone destruction in CIA [147]. IL-15 is elevated in 
synovial membrane and synovial ﬂ   uid in RA patients 
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are reduced in IL-15R-deﬁ  cient compared to wild-type 
spleen or bone marrow cells [149]. Bone mineral density 
was increased in IL-15R-deﬁ   cient mice and was not 
reduced after ovariectomy. Serum levels of TRAP5b and 
osteocalcin were lower in IL-15R-deﬁ  cient mice, consis-
tent with a low bone turnover in the absence of IL-15 
signalling.
Conclusion
Bone loss in RA patients is a frequent and clinically 
serious event. Considering bone remodelling in general, 
the balance between bone formation and bone resorption 
determines the net eﬀ  ect. In the past decade, signiﬁ  cant 
gains in knowledge about the role of bone resorption 
during chronic erosive arthritis have been made. Th  ere  is 
good evidence that inﬂ   ammation itself triggers bone 
resorption by osteoclasts [5].
Pro-inﬂ   ammatory cytokines are potent mediators of 
bone loss. Th   ese cytokines act both directly and indirectly 
to enhance osteoclastogenesis in the inﬂ  amed joint and 
systemic bone: ﬁ  rst, many pro-inﬂ  ammatory cytokines 
can alter the RANKL/OPG ratio in mesenchymal cells, 
such as osteoblasts and ﬁ  broblasts; second, some cyto-
kines, such as M-CSF and RANKL, also directly aﬀ  ect 
osteoclast diﬀ  erentiation, survival and activity.
Bone erosions and osteoporosis signiﬁ  cantly  aﬀ  ect 
function and quality of life. Th   us, anti-erosive therapies - 
besides anti-inﬂ  ammatory therapy - for RA patients are 
of great interest. In the past, bisphosphonates had been 
used to inhibit structural damage in RA joints, but the 
eﬀ  ects were limited. Recently, the anti-RANKL antibody 
denosumab has been used in RA patients in a small study 
and promising results have been observed [150]. 
Denosumab-treated RA patients showed no radiographic 
progression compared to placebo-treated patients 
Further  more, there is good evidence that TNF blockade 
also inhibits structural bone damage independent of its 
anti-inﬂ   ammatory activity in RA patients [151]. Th  us, 
our increased knowledge on the pathophysiology may 
lead to new therapeutic concepts in RA incorporating 
anti-erosive therapies. However, even nowadays up to 
80% of RA patients experience structural bone damage 
during the course of disease [152]. Th   us, further research 
is necessary to fully elucidate the pathophysiology of 
osteoclast-driven bone loss in RA patients.
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